期刊
FUTURE ONCOLOGY
卷 15, 期 11, 页码 1219-1230出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2018-0882
关键词
long-term; pancreatic neuroendocrine tumor; safety; sunitinib
类别
资金
- Pfizer Inc.
Aim: To describe the long-term safety of sunitinib in patients with progressive, well-differentiated, advanced/metastatic pancreatic neuroendocrine tumors. Patients & methods: Sunitinib- and placebo-treated patients from the Phase III study continued to receive sunitinib (37.5mg on a continuous daily-dosing regimen) in two open-label extension studies. Results: Median (range) treatment exposure: 30.2 (0.7-269.4) and 87.1 (3.9-319.4) weeks for medium-term (n=41) and long-term-treated (n=61) populations, respectively. All patients experienced 1 adverse event (AE); 47 (45.6%) reported serious AEs. Common all-causality AEs: diarrhea (63.1%); neutropenia (43.7%); abdominal pain (40.8%). Fifteen (14.6%) patients discontinued treatment due to treatment-related AEs. Conclusion: The safety of extended sunitinib treatment was consistent with the known safety profile of sunitinib in pancreatic neuroendocrine tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据